Ixoberogene soroparvovec
Experimental gene therapy
From Wikipedia, the free encyclopedia
Ixoberogene soroparvovec (Ixo-vec, also known as ADVM-022), is a gene therapy developed by Adverum Biotechnologies for wet age-related macular degeneration. It is delivered via the viral vector AAV.7m8.[1][2]